Laboratory requisitions for CJC1295(no DAC)&IPA (5mg+5mg) fail QA when specification fields are paraphrased. CJC1295(no DAC)&IPA Specification and Vial Format Review maps Growth Research catalog data on sulanpeptide.vip.
CJC1295(no DAC)&IPA is a two-peptide blend combining CJC-1295 (no DAC) and Ipamorelin for laboratory research on GHRH and ghrelin-receptor pathway signaling, growth-axis models, and peptide interaction studies without DAC-mediated albumin binding.
Researchers titrate each peptide separately before combined protocols to avoid confounding GH release kinetics. Parallel GH and prolactin immunoassays help confirm Ipamorelin selectivity claims in pituitary cell experiments.
Secretagogue combination studies appear in growth-hormone deficiency model literature as exploratory pharmacology—not treatment protocols. Combination kits pair GHRH-receptor agonism (CJC-1295 no DAC) with ghrelin-receptor selective secretagogue activity (Ipamorelin) for dual-pathway pituitary stimulation models.
Side-by-side review of specification table, vial label, and COA prevents release errors for CJC1295(no DAC)&IPA. Principal investigators should sign off CJC1295(no DAC)&IPA SKUs only after mechanism fit is documented in the study protocol.
Spec alignment: Enter exact strength notation (5mg+5mg) in procurement systems—do not round kit counts.
Catalog identifiers for CJC1295(no DAC)&IPA: CAS 863288-34-0; 170851-70-4, Formula: C152H252N44O42; C38H49N9O5. MW 3367.9 g/mol; 711.85 g/mol, purity target ≥ 99.0%. Copy these fields into requisitions and match them line-by-line on incoming COA PDFs.
Dose planning for CJC1295(no DAC)&IPA should state mass (5mg+5mg) or molarity derived from catalog molecular weight.
Publication methods should list Cat No. and mg strength for CJC1295(no DAC)&IPA to support reproducibility.
Format selection for CJC1295(no DAC)&IPA affects reconstitution math and aliquot planning. Compare available vial strengths on sulanpeptide.vip against protocol dose ranges before leadership approves a SKU; changing strength mid-study complicates comparability. Side-by-side review of catalog specification table, quote confirmation, vial label, and COA prevents release errors for CJC1295(no DAC)&IPA. QA sign-off should reference all four documents in the batch record.
Purity target ≥ 99.0% on the catalog is a specification goal. Release criteria for CJC1295(no DAC)&IPA should state whether the lot COA must meet or exceed that threshold for your Growth Research assay type. Specification alignment for CJC1295(no DAC)&IPA requires copying exact kit notation (5mg+5mg) into ERP or LIMS systems. Rounding “10mg×10 vials” to “100mg total” causes mismatches when COA lists per-vial strength and suppliers ship multi-vial kits.
Molecular identifiers for CJC1295(no DAC)&IPA—CAS 863288-34-0; 170851-70-4, molecular weight, and formula when listed—should appear on internal sample labels alongside Cat No. Publications citing CJC1295(no DAC)&IPA should include these fields for reproducibility in Growth Research journals.
Specification alignment for CJC1295(no DAC)&IPA requires copying exact kit notation (5mg+5mg) into ERP or LIMS systems. Rounding “10mg×10 vials” to “100mg total” causes mismatches when COA lists per-vial strength and suppliers ship multi-vial kits. Molecular identifiers for CJC1295(no DAC)&IPA—CAS 863288-34-0; 170851-70-4, molecular weight, and formula when listed—should appear on internal sample labels alongside Cat No. Publications citing CJC1295(no DAC)&IPA should include these fields for reproducibility in Growth Research journals.
Purity target ≥ 99.0% on the catalog is a specification goal. Release criteria for CJC1295(no DAC)&IPA should state whether the lot COA must meet or exceed that threshold for your Growth Research assay type.
CJC1295(no DAC)&IPA from Sulan Peptide Official is for research use only (RUO)—not for human or veterinary use. Questions: Contact page or WhatsApp on sulanpeptide.vip.